The Dales Report
Mar 18, 2023
A TDR Psychedelics Exclusive, Dr. Jeannie Fontana, MD PHD discusses TREAT California's $5 Billion goal to improve mental healthcare, and explore the critical aspects of funding advanced treatments like psychedelic-assisted therapies that can revolutionize the healthcare system.
In our latest TDR Psychedelics Exclusive, we welcome the founder and CEO of TREAT California, Dr. Jeannie Fontana, MD PHD to discuss their agency’s $5 Billion goal to improve mental healthcare, and explore the critical aspects of funding advanced treatments like psychedelic-assisted therapies that can revolutionize the healthcare system. We differentiate the company’s processes and funding model from private equities, and how development facilities would benefit from their exclusive terms in order to deliver better and more accessible mental health treatments for all. We also discuss the various stages involved in bringing these treatments to market, and the critical role that timely funding plays in expediting this process. TREAT California is a combined public-private fund that acts like a venture capital, funding revolutionary treatments. Join us as we dive deeper in understanding their campaign for psychedelic-assisted treatments, its advantages, as well as challenges and ethical considerations it will face. Is this the perfect mental healthcare framework?